Evidence for Structural and Functional Damage of the Inner Retina in Diabetes With No Diabetic Retinopathy.
Montesano Giovanni, Ometto Giovanni, Higgins Bethany E, Das Radha, Graham Katie W, Chakravarthy Usha, McGuiness Bernadette, Young Ian S, Kee Frank, Wright David M
AI Summary
This study found early inner retinal thinning and functional loss in diabetes, even before visible vascular changes, indicating neuronal damage occurs very early in the disease.
Abstract
Purpose
To provide structural and functional evidence of inner retinal loss in diabetes prior to vascular changes and interpret the structure-function relationship in the context of an established neural model.
Methods
Data from one eye of 505 participants (134 with diabetes and no clinically evident vascular alterations of the retina) were included in this analysis. The data were collected as part of a large population-based study. Functional tests included best-corrected visual acuity, Pelli-Robson contrast sensitivity, mesopic microperimetry, and frequency doubling technology perimetry (FDT). Macular optical coherence tomography volume scans were collected for all participants. To interpret the structure-function relationship in the context of a neural model, ganglion cell layer (GCL) thickness was converted to local ganglion cell (GC) counts.
Results
The GCL and inner plexiform layer were significantly thinner in participants with diabetes (P < 0.05), with no significant differences in the macular retinal nerve fiber layer or the outer retina. All functional tests except microperimetry showed a significant loss in diabetic patients (P < 0.05). Both FDT and microperimetry showed a significant relationship with the GC count (P < 0.05), consistent with predictions from a neural model for partial summation conditions. However, the FDT captured additional significant damage (P = 0.03) unexplained by the structural loss.
Conclusions
Functional and structural measurements support early neuronal loss in diabetes. The structure-function relationship follows the predictions from an established neural model. Functional tests could be improved to operate in total summation conditions in the macula, becoming more sensitive to early loss.
MeSH Terms
Shields Classification
Key Concepts5
The ganglion cell layer (GCL) and inner plexiform layer were significantly thinner in participants with diabetes and no clinically evident vascular alterations of the retina (P < 0.05), with no significant differences in the macular retinal nerve fiber layer or the outer retina.
All functional tests except mesopic microperimetry showed a significant loss in diabetic patients with no clinically evident vascular alterations of the retina (P < 0.05). Functional tests included best-corrected visual acuity, Pelli-Robson contrast sensitivity, and frequency doubling technology (FDT) perimetry.
Both frequency doubling technology (FDT) perimetry and mesopic microperimetry showed a significant relationship with the ganglion cell (GC) count (P < 0.05) in participants with diabetes and no clinically evident vascular alterations of the retina, consistent with predictions from a neural model for partial summation conditions.
Frequency doubling technology (FDT) perimetry captured additional significant damage (P = 0.03) unexplained by the structural loss in participants with diabetes and no clinically evident vascular alterations of the retina.
Functional and structural measurements support early neuronal loss in diabetes prior to vascular changes.
Related Articles5
Evaluation of Visual Cortex Activity Using Functional Near-Infrared Spectroscopy in Primary Open Angle and Primary Angle Closure Glaucoma: A Pilot Study.
Cross-Sectional StudyThe Mechanism of Macular Sparing.
ReviewPhosphenes electrically evoked with DTL electrodes: a study in patients with retinitis pigmentosa, glaucoma, and homonymous visual field loss and normal subjects.
Clinical TrialResidual visual function after loss of both cerebral hemispheres in infancy.
Case SeriesVisual training of cerebral blindness patients gradually enlarges the visual field.
Clinical TrialIs this article assigned to the wrong chapter(s)? Let us know.